Insider Buying: VolitionRx Limited (NYSE:VNRX) CEO Acquires 181,818 Shares of Stock

VolitionRx Limited (NYSE:VNRX) CEO Cameron John Reynolds acquired 181,818 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

VolitionRx Price Performance

Shares of VNRX stock opened at $0.53 on Friday. The company’s 50-day simple moving average is $0.59 and its two-hundred day simple moving average is $0.64. The company has a market capitalization of $48.93 million, a P/E ratio of -1.47 and a beta of 1.09. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.02.

Institutional Trading of VolitionRx

Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter worth $36,000. Northern Trust Corp boosted its position in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on VNRX shares. D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research report on Thursday, March 20th. StockNews.com started coverage on shares of VolitionRx in a research note on Friday. They set a “sell” rating for the company.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.